Incidence of thromboembolism and associated factors in multiple myeloma patients treated with immunomodulatory drugs: a retrospective analysis in Belo Horizonte, Brazil-Reference-Cited by-同舟云学术

Incidence of thromboembolism and associated factors in multiple myeloma patients treated with immunomodulatory drugs: a retrospective analysis in Belo Horizonte, Brazil

Published:2023-12-16 Issue:1 Volume:32 Page:
ISSN:0941-4355
Container-title:Supportive Care in Cancer
language:en
Short-container-title:Support Care Cancer

Author:

da Costa Iwyson Henrique Fernandes,de Pádua Cristiane Aparecida Menezes,de Miranda Drummond Paula Lana,Silveira Lívia Pena,Malta Jéssica Soares,dos Santos Roberta Márcia Marques,Reis Adriano Max Moreira

Publisher

Springer Science and Business Media LLC

Subject

Oncology

Link

https://link.springer.com/content/pdf/10.1007/s00520-023-08251-y.pdf

Reference32 articles.

1. Patel JN, Robinson M, Jagosky M, Slaughter D, Arnall J, Jandrisevits E et al (2021) Thromboembolism incidence and risk factors in multiple myeloma after first exposure to immunomodulatory drug–based regimens. Clin Lymphoma Myeloma Leuk 21(3):188–198.e2

2. Chakraborty R, Bin Riaz I, Malik SU, Marneni N, Mejia Garcia A, Anwer F et al (2020) Venous thromboembolism risk with contemporary lenalidomide-based regimens despite thromboprophylaxis in multiple myeloma: a systematic review and meta-analysis. Cancer 126(8):1640–1650

3. Takaishi K, Tsukamoto S, Ohwada C, Takeuchi M, Kawasaki Y, Nagai Y et al (2019) Low incidence of thromboembolism in multiple myeloma patients receiving immunomodulatory drugs; a retrospective single-institution analysis. J Thromb Thrombolysis 48(1):141–148

4. Anderson SM, Beck B, Sterud S, Lockhorst R, Ngorsuraches S (2019) Evaluating the use of appropriate anticoagulation with lenalidomide and pomalidomide in patients with multiple myeloma. J Oncol Pharm Pract 25(4):806–812

5. Kato A, Takano H, Ichikawa A, Koshino M, Igarashi A, Hattori K et al (2013) A retrospective cohort study of venous thromboembolism(VTE) in 1035 Japanese myeloma patients treated with thalidomide; lower incidence without statistically significant association between specific risk factors and development of VTE and effects of thromboprophylaxis with aspirin and warfarin. Thromb Res 131(2):140–144